The Green Cross’s ‘Shinbaro’ has been approved for its safety and effectiveness in its Phase 4 clinical trial
Green Cross (President Eun-chul Huh) announced on the 7th that it unveiled the Pharse 4 clinical trial result of the arthritis treatment ‘Shinbaro Cap’ in its poster session at the 2015 Osteoarthritis Research Society International (OARSI) held from the 28th of the last month to the 3rd in Seattl...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
